Kornimate/medical-research-clean huggingface dataset:
multi-omics testing for immunotherapy efficacy evaluation (motivation)

Conditions: Non-small Cell Lung Cancer; Neoantigen; Next-generation Sequencing; Biomarker

Summary: this multicenter prospective observational and exploratory study aims to develop and validate a novel multi-omics-based computational method for neoantigen prediction in non-small cell lung cancer (nsclc), and discover biomarkers for evaluation of pd-1/pd-l1 inhibitor's efficacy in patients of advanced nsclc.

tumor tissues and blood samples from about 400 patients with non-small-cell lung cancer (nsclc) will be collected for the study, which will be subject to ngs-based genomic, transcriptomic, and methylomic profiling in order to construct a multi-omics landscape of nsclc. these multi-omics data will be used to construct and validate a novel computational method for neoantigen prediction. additionally, biomarkers will be explored for prognosis and patient stratification, as well as for evaluation of pd-1/pd-l1 inhibitor treatment efficacy in patients of advanced nsclc.

Eligibility criteria:
inclusion criteria: * patients with stage i-iv non-small cell lung cancer(with no restriction of age, gender, or smoking history) * patients in the group will be allowed to collect whole blood and tissue samples at specific time points * eastern cooperative oncology group performance status of 0-1 within 28 days prior to registration * no previous systemic anti-tumor therapy * signed informed consent exclusion criteria: * active or history of autoimmune disease or immune deficiency * patients with serious mental disease * prior allogeneic stem cell or solid organ transplantation * pregnant or lactating women * patients who cannot obtain tumor tissue samples and / or whole blood * patients with history of blood transfusion within half a year * patients with any other malignancy diagnosed within 5 years * received systemic anti-tumor therapy
external validation of irriv test relationship with renal functional reserve

Conditions: Acute Kidney Injury

Summary: the assessment of renal functional reserve (rfr) has been proposed for the risk stratification of patients undergoing potentially nephrotoxic procedures. the investigators hypothesized that there is a correlation between irriv and rfr under normal conditions. for this purpose, externally validation of irriv test is performed in a validation cohort of healthy subjects.

normal subjects display a significant capacity to increase in baseline gfr under physiological needs (e.g. pregnancy) or pathological states (e.g. solitary kidney). this capacity is known as renal functional reserve (rfr), and it is calculated as the difference between the measured maximum gfr achieved through a renal stress test and the baseline gfr measured in rest conditions.in clinical practice, the most common renal stress test is performed as a standardized protein loading test. in a pilot study, the investigators demonstrated a significant correlation between rfr and the intra-parenchymal renal resistive index variation (irriv) during an echo renal stress test in a cohort of healthy volunteers. irriv test has proven to be rapid, safe, bedside and easy to perform and it might represent a preliminary test in screening patients' rfr. for this purpose, externally validation of irriv test is performed in a validation cohort of healthy subjects.

Eligibility criteria:
inclusion criteria were: * age more than 18 years old; * baseline estimated gfr, calculated using the chronic kidney disease epidemiology collaboration (ckd-epi) equation, greater than or equal to 60 ml/min/1.73 m2. exclusion criteria were: * age less than 18 years old; * comorbidities potentially affecting renal function (i.e. arterial hypertension, diabetes, vasculopathy, etc.; * chronic administration of drugs able to modify renal blood flow and/or gfr (angiotensin converting enzyme-inhibitors (acei), angiotensin receptor blockers (arb), calcium channel blockers, loop diuretics etc.); * pregnancy; * ultrasound evidence of morphological kidney abnormalities and/or renal artery stenosis; * nonsteroidal anti-inflammatory drugs (nsaids) or contrast media in the 2 days before the tests.

Keywords: acute kidney injury colordoppler irriv test renal functional reserve renal resistive index ultrasound
application of transcranial alternating current stimulation for modulation of sleep and cognitive performance

Conditions: Mild Cognitive Impairment

Summary: loss of slow wave sleep (sws) is common in mild cognitive impairment (mci) and alzheimer's disease, and is thought to worsen thinking, memory and brain degeneration. initial studies suggest that correction of sleep deterioration may slow the progression of brain damage in mild cognitive impairment, and might be able to stop the development of alzheimer's disease. transcranial alternating current stimulation (tacs) uses electrodes to deliver very small amounts of electricity through the brain, with direct effects on brain cell function. transcranial electric stimulation has been demonstrated to enhance slow wave sleep and to improve memory when applied during sleep in healthy adults. the purpose of this research is to investigate tacs to modulate sleep, thinking/memory, mood, and quality of life among normal healthy adults, older adults, as well as individuals with mci.


Eligibility criteria:
inclusion criteria: * ages 18-85 * native english speakers * neurological diagnosis of amnestic mild cognitive impairment (amci) exclusion criteria: * brain tumors * skull defects * epilepsy * metal implants/devices above the neck * eczema or sensitive skin * insomnia * sleep apnea that requires use of a cpap machine * rapid eye movement (rem)-sleep behavior disorder * currently pregnant or trying to become pregnant during the study period * diagnosis of cognitive impairment \*cognitive impairment required for mci arms
non-small cell lung cancer and quality of life

Conditions: Non Small Cell Lung Cancer

Summary: the principal objective is to study clinical observations, symptoms and quality of life of non-small-cell lung cancer (nsclc) patients undergoing specific non-operative treatment for cancer, including chemotherapy and radiotherapy.


Eligibility criteria:
inclusion criteria: * patients with verified nsclc * after the nsclc diagnosis has been confirmed prior to first chemotherapy or radiotherapy * finnish speaking patients * aged 18 years or more * written informed consent has to be signed exclusion criteria: * patients not consenting to participate in the study * patients not able to communicate sufficiently * cancer type is other than non-small-cell lung cancer

Keywords: quality of life symptoms
prophylactic central neck dissection for papillary thyroid cancer

Conditions: Papillary Thyroid Cancer

Summary: the purpose of this study is to determine whether prophylactic central neck dissection is beneficial for patients with papillary thyroid cancer staged preoperatively as node negative.

several respected organizations have recently recommended that total thyroidectomy plus prophylactic central neck dissection should be the standard operation for papillary thyroid cancer. however, it is still unclear if this approach has any benefit on survival or locoregional control of the disease. in addition, potential advantages of this more aggressive surgical approach should outweigh the risk of morbidity. the purpose of this retrospective cohort study is to determine whether prophylactic central neck dissection is beneficial for patients with papillary thyroid cancer staged preoperatively as node negative. in this study outcomes of total thyroidectomy versus this plus prophylactic central neck dissection for papillary thyroid cancer are compared in a 10-year follow-up. patients operated between 1993 and 1997 (n=282) underwent total thyroidectomy alone, whereas patients operated between 1998 and 2002 (n=358) underwent total thyroidectomy plus prophylactic central neck dissection.

Eligibility criteria:
inclusion criteria: * a pathological diagnosis of papillary thyroid cancer, * in a patient with negative cervical lymph nodes on pre-, or intraoperative evaluation exclusion criteria: * incidental diagnosis of papillary thyroid cancer following hemithyroidectomy and requiring completion thyroidectomy, * one-stage lymph nodes dissection based on therapeutic intent, * previous thyroid surgery, * incomplete follow-up information, * incomplete histopathology report, * asa grade higher than 3 (american society of anesthesiology)

Keywords: papillary thyroid cancer central neck dissection survival locoregional control morbidity
nasal packing duration and development of pharyngitis after septorhinoplasty surgery

Conditions: Rhinitis

Summary: septoplasty or septal reconstruction is a corrective surgical procedure performed to straighten the nasal septum. it may be associated with numerous complications. to minimize these complications, both nasal cavities are frequently packed with different types of nasal packing. in our study we will try to find relationship between duration of nasal packing and postrhinoplasty sore throat and pharyngitis.

nasal packing affects swallowing by different mechanisms. it may affect swallowing as a result of nasal congestion, constant mouth breathing, throat dryness and pharyngitis. postoperative sore throat causes patient dissatisfaction and poor pain control. several interventions could be performed to reduce sore throat and pharyngitis and increase patient satisfaction , which may not be convenient for all patients, such as gargling or sprays

Eligibility criteria:
inclusion criteria: * asa i and ii patients * aged from 20 to 40 years old * undergo septorhinoplasty exclusion criteria: * bleeding disorders * uncontrolled hypertension * cardiovascular diseases * uncontrolled diabetes mellitus * collagen disorders * pregnancy
study of a novel thrombectomy device to treat acute iliofemoral deep venous thrombosis

Conditions: Venous Thrombosis

Summary: the purpose of this study is to determine whether the novel aspiration thrombectomy device combined with catheter-directed thrombolysis is effective in the treatment of acute iliofemoral deep venous thrombosis (if-dvt).

catheter-directed thrombolysis will be performed in eligible patients with acute if-dvt. a combined mechanical thrombectomy will be used to clear the iliac thrombi in experimental group. the immediate, mid- and long-term outcomes will be recorded. quantitative data wiil be expressed as mean ± sd, and will be compared with independent-sample t-test or paired-sample t-test. count data will be expressed as a ratio (or percentage), and the chi-square test or the fisher's exact test will be used for comparisons. a difference with p \< 0.05 will be considered statistically significant. all statistical analyses will be performed using ibm spss, version 22.0 (spss inc., chicago, il, usa).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of iliofemoral deep venous thrombosis * symptoms of less than 14 days' duration * with good function status * a life expectancy of more than 1 year * a low risk of bleeding exclusion criteria: * without iliac vein thrombosis * anticoagulation and/or thrombolysis contraindications * systemic infection * heart, hepatic, renal function insufficiency
a phase ib study of hs-10370 in addition to other anti-cancer therapies in patients with advanced solid tumors

Conditions: Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer

Summary: this is a phase ib study that will evaluate the safety, tolerability , pharmacokinetics, activity and immunogenicity of hs-10370 in combination with other anti-cancer therapies in chinese patients with kras g12c mutation advanced or metastatic solid tumors, especially in and colorectal cancer(crc) and non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * men or women greater than or equal to 18 years * at least one measurable lesion in accordance with recist 1.1 * must have an ecog performance status of 0 or 1. * patients with advanced solid tumors who have failed after adequate standard treatment, are intolerant to standard treatment, or have no standard treatment available. * documentation of the presence of a kras g12c mutation * estimated life expectancy ≥12 weeks. * reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.men also consent to use adequate contraceptive method within the same time limit. * the subjects are able to comply with the process of the protocol. exclusion criteria: * treatment with any of the following: previous or current treatment with other kras g12c inhibitors. * active brain metastases. * patients with uncontrolled pleural, ascites or pericardial effusion * spinal cord compression * presence of grade ≥ 2 toxicities due to prior anti-tumor therapy. * subjects with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for kras g12c. * history of other primary malignancies. * inadequate bone marrow reserve or organ functions. * abnormal cardiac examination results. * severe, uncontrolled or active cardiovascular disorders. * diabetes ketoacidosis or hyperglycemia hyperosmolality * uncontrolled hypertension. * severe bleeding symptoms or bleeding tendencies. * severe arteriovenous thrombosis occurred * serious infection. * continuous use of glucocorticoids * active infectious diseases. * refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications * hepatic encephalopathy, hepatorenal syndrome, or ≥ child pugh b-grade cirrhosis. * interstitial lung disease (ild). * serious neurological or mental disorders. * active autoimmune diseases
a placebo-controlled study of collagen hydrolysate in subjects with knee osteoarthritis (oa)

Conditions: Knee Osteoarthritis (OA)

Summary: this study is designed to evaluate, by mri, knee cartilage and structure in all subjects. half the subjects in this study will take collagen hydrolysate each day for 48 weeks and the other half of the subjects will take a placebo dose, that looks like and tastes like the collagen hydrolysate, each day for 48 weeks. mris will be taken at study weeks -1, 24, and 48.

this is a single-site, double-blind, pilot study to evaluate the sensitivity of mri to detect cartilage structure and composition in subjects taking daily oral collagen hydrolysate (a nutritional supplement) or placebo for 48 weeks. 30 subjects will be randomized to collagen hydrolysate or placebo (1:1 ratio). the goal is to evaluate, by mri, knee cartilage and structure in all subjects. the primary functional outcome measure will be the womac questionnaire and the primary pathological outcome measure will be knee cartilage structure and composition as measurements done by mri imaging. subjects will have contrast dgemric mris done at study weeks -1, 24 and 48.

Eligibility criteria:
inclusion criteria: * age \> 49 years * chronic knee discomfort based on the affirmative response to the question "during the past 6 months, have you had any pain in the knee more than half the days of the month ?" * womac pain subscale score ≥ 1 * tibiofemoral or patellofemoral osteoarthritis on anteroposterior weight-bearing semi-flexed or lateral knee radiographs with at least one osteophyte and no significant joint-space-narrowing * clinical examination confirming knee pain or discomfort referable to the knee joint * prepared to refrain from use of glucosamine, chondroitin, same and doxycycline * stable medication and/or supplement use exclusion criteria: * use of glucosamine, chondroitin, diacerein or doxycycline within 14 weeks prior to randomization * serious medical conditions or impairments that, in the view of the investigator, would obstruct their participation in the trial * individuals who are expected not to comply with the study protocol * plan to permanently relocate from the region during the trial period * planned knee arthroplasty in the study knee * active pathology of confounding origin which may cause pain, extending to the knee * pregnancy * any contra-indication to having an mri scan

Keywords: oa knee arthritis osteoarthritis nutritional supplement cam mri
gene molecular alterations as disease prognostic markers in patients with non-small cell lung cancer (nsclc)

Conditions: NSCLC (Non-small Cell Lung Cancer)

Summary: gema-pron is an observational, multicenter, single cohort, retrospective clinical trial. the aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (nsclc).

this a non- interventional, multicenter, retrospective one arm trial assessing patients with histologically confirmed diagnosis of non-small cell lung cancer (nsclc). patients received treatment in 18 hellenic cooperative oncology group (hecog)- affiliated centers in greece between 2000 and 2020. molecular genetic alterations, including single nucleotide variants, copy number alterations, and translocations, are detected with next generation sequencing using the foresentia® nsclc panel developed by nipd genetics. the aim of the trial is to assess the prevalence and prognostic value of molecular alterations in the study population.

Eligibility criteria:
inclusion criteria: * age 18 and above. * histologically confirmed non-small cell lung cancer (nsclc). * adequate, and suitable tissue for the testing of somatic genetic alterations. exclusion criteria: - patients with personal medical history of malignancy, other than non-small cell lung cancer (nsclc), with the exclusion of completely resected non-melanoma skin cancers, in situ carcinomas of the cervix uteri, in situ bladder carcinomas, in situ ductal breast carcinoma, and other cancers treated with curative intent with no evidence of disease recurrence for 5 years.

Keywords: nsclc non-small cell lung cancer early stage non-small cell lung cancer metastatic non-small cell lung cancer mutations copy number alterations translocations cna pd-l1 expression tumor infiltrating lymphocytes tils pathogenic single nucleotide variants
hla-mismatched mst vs hla-matched nst for aml in intermediate-risk

Conditions: Acute Myeloid Leukemia

Summary: patients with de novo aml enrolled in the study. patient who has a hla-identical donor is assigned to receive nst therapy with gvhd prophylaxis and who has no hla-identical donor is assigned to receive mst therapy without gvhd prophylaxis.

the optimal therapy for intermediate-risk patients with acute myeloid leukemia (aml) in first complete remission (cr1) is uncertain. recent studies shown that microtransplantation (mst) can improve survival in aml-cr1 patients. however, a comparison study between the mst and nonmyeloablative stem cell transplantation (nst) is lacking. 156 intermediate-risk aml-cr1 patients aged 9 to 59 years were enrolled in this study. patients with de novo aml enrolled in the study. patient who has a hla-identical donor is assigned to receive nst therapy with gvhd prophylaxis and who has no hla-identical donor is assigned to receive mst therapy without gvhd prophylaxis.

Eligibility criteria:
inclusion criteria: * patients must have elderly (9-59 ages) aml pathologically confirmed per who guidelines. * patients with intermediate-risk aml-cr1 * patients must have ecog performance status of 0,1,or 2. if ecog 2. * patients must have a hla mismatched donor who should be able to provide informed consent. * all genders and races are eligible. * alt and ast≤3 ×uln, tbil≤1.5 × uln, cr≤2 ×uln or crcl≥40 ml/min * by means of ultrasonic heartbeat map or multiple gated acquisition (muga) scanning determination of lvef in the normal range. * donors must be able to safely undergo leukapheresis. exclusion criteria: * received operation 4 weeks before randomization * acute promyelocytic leukemia,myeloid sarcoma, chronic myeloid leukemia in accelerated phase and blastic phase; * active cns disease, pregnancy, or other major medical or psychiatric illnesses that could compromise tolerance to this protocol * require the use of warfarin or equivalent of vitamin k antagonists (such as phenprocoumon) anticoagulant. * there is clinical significance of cardiovascular disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months before randomization, or any heart function grade 3 (moderate) or 4 (severe ) heart disease in accordance with the functional classification method of new york heart association (nyha). * known to have the following history: human immunodeficiency virus (hiv) or active hepatitis c virus or hepatitis b virus infection * any situation processed by the pi that will be damaged to the patients safety. * patients and / or authorized family member refuse to sign the consent. attend other clinical researchers in 3 months. * donors exclusion criteria include:active infection or malignancy, cardiovascular instability, severe anemia, severe coagulation disorder, pregnancy, inadequate venous access, inability to provide consent, or any other condition deemed unsafe by the treatment staff.

Keywords: acute myeloid leukemia microtransplantationhla-mismatched microtransplantation nonmyeloablative stem cell transplantation graft-versus-host disease
the effect of human recombinant erythropoietin in acute renal failure

Conditions: Acute Kidney Injury

Summary: the purpose of this study is to determine if the use of erythropoietin when used in high dose during acute kidney injury can decrease the number of days of kidney injury.

acute kidney injury is associated with increased morbidity. the most common injury to the kidney occurs during hospitalization with either ischemic or nephrotoxic insult to the kidney. this can prolong hospitalization and depending on the severity of the insult result in permanent decreased kidney function. recent studies in animals have suggested benefits of using erythropoietin in high doses at time of kidney injury with eividence for less injury in the kidney tissue of those animals who received treatment compared to those animals that received only saline. limited human data also suggests that use of high dose erythropoietin at the time of stroke can decrease the extent of brain injury. in addition cardiac cell culture studies also have shown decrease in cell injury with use of erythropoietin. these studies have prompted us to evaluate if admininstering erythropoietin to those with onset of acute kidney injury during their hospitalization may benefit from this intervention. this pilot study then evaluates that use of high dose erythropoietin administed daily over 3 days in patients with acute kidney injury on whether the days spent in renal failure are less than those who will receive no study medication. those patients with kidney failure from either ischemic or nephrotoxic insult and no other contraindication to erythropoietin use will be considered for the study. informed consent is obtained from the patient or next of kin

Eligibility criteria:
inclusion criteria: * age equal or greater than 21 yo * acute neprhotoxic or ischemic kidney injury, acute tubular necrosis exclusion criteria: * no active or current malignancies * not actively receiveing epo * gfr less than 60 ml/min * unable to provide informed consent * contraindication to erythropoietin use
efficacy and safety of auto-fmt in preventing agvhd

Conditions: Graft Versus Host Disease, Acute

Summary: to evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. bone marrow transplant patients were recruited.


Eligibility criteria:
inclusion criteria: * haplo-hsct patients; bacteroidetes \>0.1%; inverse simpson diversity ≥2 exclusion criteria: * gastrointestinal diseases；age\>60; or age\<10；probiotics or prebiotics were taken before enrollment